Yeoun Jin Kim

Yeoun Jin Kim

Auto-generated profile, based on publicly available information

Yeoun Jin Kim

Biomarker Science and Technologies, Early Oncology

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PZPeter Zanvit
Peter Zanvit
DDDewald van Dyk
Dewald van Dyk
CFChristine Fazenbaker
Christine Fazenbaker
KMKelly McGlinchey
Kelly McGlinchey
WLWeichuan Luo
Weichuan Luo
EBEmily E. Bosco
Emily E. Bosco
Prostate cancer is generally considered an immunologically “cold” tumor type that is insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent antitumor immune response to “heat up” the tumor microenvironment. However, many antigens expressed on prostate tumor cells are also found on normal tissues, potentially causing on-target, off-tumor toxicities and a suboptimal therapeutic index. Our studies revealed that six-transmembrane epithelial antigen of prostate-2 (STEAP2) was a prevalent prostate cancer antigen that displayed high, homogeneous cell surface expression across all stages of disease with limited distal normal tissue expression, making it ideal for therapeutic targeting. A multifaceted lead generation approach enabled development of an armored STEAP2 chimeric antigen receptor T cell (CAR-T) therapeutic candidate, AZD0754. This CAR-T product was armored with a dominant-negative TGF-β type II receptor, bolstering its activity in the TGF-β–rich immunosuppressive environment of prostate cancer. AZD0754 demonstrated potent and specific cytotoxicity against antigen-expressing cells in vitro despite TGF-β–rich conditions. Further, AZD0754 enforced robust, dose-dependent in vivo efficacy in STEAP2-expressing cancer cell line–derived and patient-derived xenograft mouse models, and exhibited encouraging preclinical safety. Together, these data underscore the therapeutic tractability of STEAP2 in prostate cancer as well as build confidence in the specificity, potency, and tolerability of this potentially first-in-class CAR-T therapy.

16 July 2015 in Proteomics
Verified
Journal Article
Closed access
PDF file
YKYeoun Jin Kim
Yeoun Jin Kim
SGSebastien Gallien
Sebastien Gallien
VKVictoria EL KHOURY
Victoria EL KHOURY
PGPanchali Goswami
Panchali Goswami
KSKatriina Sertamo
Katriina Sertamo
BDBruno Domon
Bruno Domon

16 August 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSSteve Sweet
Steve Sweet
DCDavid Chain
David Chain
Wen YuWen Yu
Wen Yu
PMPhilip Martin
Philip Martin
MRMarlon Rebelatto
Marlon Rebelatto
YKYeoun Jin Kim
Yeoun Jin Kim
Mass spectrometry-based targeted proteomics allows objective protein quantitation of clinical biomarkers from a single section of formalin-fixed, paraffin-embedded (FFPE) tumor tissue biopsies. We combined high-field asymmetric waveform ion mobility spectrometry (FAIMS) and parallel reaction monitoring (PRM) to increase assay sensitivity. The modular nature of the FAIMS source allowed direct comparison of the performance of FAIMS-PRM to PRM. Limits of quantitation were determined by spiking synthetic peptides into a human spleen matrix. In addition, 20 clinical samples were analyzed using FAIMS-PRM and the quantitation of HER2 was compared with that obtained with the Ventana immunohistochemistry assay. FAIMS-PRM improved the overall signal-to-noise ratio over that from PRM and increased assay sensitivity in FFPE tissue analysis for four (HER2, EGFR, cMET, and KRAS) of five proteins of clinical interest. FAIMS-PRM enabled sensitive quantitation of basal HER2 expression in breast cancer samples classified as HER2 negative by immunohistochemistry. Furthermore, we determined the degree of FAIMS-dependent background reduction and showed that this correlated with an improved lower limit of quantitation with FAIMS. FAIMS-PRM is anticipated to benefit clinical trials in which multiple biomarker questions must be addressed and the availability of tumor biopsy samples is limited.

19 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
VKVictoria EL KHOURY
Victoria EL KHOURY
ASAnna Schritz
Anna Schritz
SKSang-Yoon Kim
Sang-Yoon Kim
ALAntoine LESUR
Antoine LESUR
KSKatriina Sertamo
Katriina Sertamo
YKYeoun Jin Kim
Yeoun Jin Kim
Lung cancer is the deadliest cancer worldwide, mainly due to its advanced stage at the time of diagnosis. A non-invasive method for its early detection remains mandatory to improve patients’ survival. Plasma levels of 351 proteins were quantified by Liquid Chromatography-Parallel Reaction Monitoring (LC-PRM)-based mass spectrometry in 128 lung cancer patients and 93 healthy donors. Bootstrap sampling and least absolute shrinkage and selection operator (LASSO) penalization were used to find the best protein combination for outcome prediction. The PanelomiX platform was used to select the optimal biomarker thresholds. The panel was validated in 48 patients and 49 healthy volunteers. A 6-protein panel clearly distinguished lung cancer from healthy individuals. The panel displayed excellent performance: area under the receiver operating characteristic curve (AUC) = 0.999, positive predictive value (PPV) = 0.992, negative predictive value (NPV) = 0.989, specificity = 0.989 and sensitivity = 0.992. The panel detected lung cancer independently of the disease stage. The 6-protein panel and other sub-combinations displayed excellent results in the validation dataset. In conclusion, we identified a blood-based 6-protein panel as a diagnostic tool in lung cancer. Used as a routine test for high- and average-risk individuals, it may complement currently adopted techniques in lung cancer screening.

12 December 2018 in Journal of Proteome Research
Verified
Journal Article
Closed access
YKYeoun Jin Kim
Yeoun Jin Kim
SSSteve Sweet
Steve Sweet
JEJarrett D. Egertson
Jarrett D. Egertson
ASAndrew J. Sedgewick
Andrew J. Sedgewick
SWSunghee Woo
Sunghee Woo
THTodd Hembrough
Todd Hembrough

30 September 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
ACAndrew G. Chambers
Andrew G. Chambers
SSSteve Sweet
Steve Sweet
DCDavid Chain
David Chain
YKYeoun Jin Kim
Yeoun Jin Kim